[go: up one dir, main page]

MX2010010393A - Uso de la catepsina c. - Google Patents

Uso de la catepsina c.

Info

Publication number
MX2010010393A
MX2010010393A MX2010010393A MX2010010393A MX2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A
Authority
MX
Mexico
Prior art keywords
cathepsin
pain
aspects
treatment
present
Prior art date
Application number
MX2010010393A
Other languages
English (en)
Inventor
Martin Michaelis
Mathias Gebauer
Danping Ding-Pfennigdorff
Anke M Schulte
Christiane Metz-Weidmann
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010010393A publication Critical patent/MX2010010393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere al uso de Catepsina C. Otros aspectos de la invención se refieren a métodos para investigar fármacos, para diagnosticar susceptibilidad al dolor y para el tratamiento del dolor.
MX2010010393A 2008-03-26 2009-03-21 Uso de la catepsina c. MX2010010393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290285A EP2105742A1 (en) 2008-03-26 2008-03-26 Use of cathepsin C
PCT/EP2009/002091 WO2009118137A1 (en) 2008-03-26 2009-03-21 Use of cathepsin c

Publications (1)

Publication Number Publication Date
MX2010010393A true MX2010010393A (es) 2010-10-20

Family

ID=39720231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010393A MX2010010393A (es) 2008-03-26 2009-03-21 Uso de la catepsina c.

Country Status (14)

Country Link
US (1) US8349567B2 (es)
EP (2) EP2105742A1 (es)
JP (1) JP5748652B2 (es)
KR (1) KR101621273B1 (es)
CN (1) CN102150046B (es)
AR (1) AR071034A1 (es)
AU (1) AU2009228611B2 (es)
BR (1) BRPI0909223A2 (es)
CA (1) CA2719062A1 (es)
IL (1) IL208236A (es)
MX (1) MX2010010393A (es)
MY (1) MY155340A (es)
TW (1) TWI510784B (es)
WO (1) WO2009118137A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2293072A1 (en) * 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
JP5939994B2 (ja) * 2010-03-18 2016-06-29 サノフイ 疼痛に関係する化合物を識別することに関する方法及び使用並びに痛覚過敏を診断する方法
EP2390348A1 (en) * 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390349A1 (en) * 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
TW201604280A (zh) * 2010-07-07 2016-02-01 第一三共股份有限公司 具有增進外來基因表現之ｄｎａ分子
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2012168453A1 (en) * 2011-06-10 2012-12-13 Sanofi Methods and uses relating to the diagnosis or prognosis of pain-related tissue states or pain-related diseases such as pain
CN111820188B (zh) * 2020-08-04 2021-10-29 中山大学附属第一医院 一种类哮喘慢阻肺重叠气道炎症小鼠模型的建立方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
PT889723E (pt) 1996-03-25 2002-11-29 Lohmann Therapie Syst Lts Sistema terapeutico transdermico com pequena espressura da zona de aplicacao e elevada flexibilidade assim como processo de producao
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
WO2004077053A1 (en) * 2003-02-25 2004-09-10 Biofrontera Pharmaceuticals Gmbh Cathepsin y for the treatment of pain
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US20070286854A1 (en) * 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
EP1595945A1 (en) 2004-05-14 2005-11-16 Boehringer Ingelheim International GmbH Screening method for identifying compounds that have the ability to inhibit the activity of Myc
US20080311036A1 (en) * 2005-05-11 2008-12-18 University Of Florida Research Foundation, Inc. Imaging of Neural and Organ Injury or Damage
GB0521512D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL208236A0 (en) 2010-12-30
US20110091888A1 (en) 2011-04-21
TW201000905A (en) 2010-01-01
CN102150046B (zh) 2016-01-06
AU2009228611A1 (en) 2009-10-01
WO2009118137A1 (en) 2009-10-01
KR20100128298A (ko) 2010-12-07
EP2260306B1 (en) 2014-07-16
JP5748652B2 (ja) 2015-07-15
BRPI0909223A2 (pt) 2015-12-01
KR101621273B1 (ko) 2016-05-16
EP2105742A1 (en) 2009-09-30
IL208236A (en) 2014-06-30
EP2260306A1 (en) 2010-12-15
US8349567B2 (en) 2013-01-08
AU2009228611B2 (en) 2014-03-20
HK1160925A1 (zh) 2012-08-17
CN102150046A (zh) 2011-08-10
CA2719062A1 (en) 2009-10-01
MY155340A (en) 2015-10-15
AR071034A1 (es) 2010-05-19
TWI510784B (zh) 2015-12-01
JP2011526143A (ja) 2011-10-06

Similar Documents

Publication Publication Date Title
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX355543B (es) Macrociclos peptidomiméticos.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MY155340A (en) Use of cathepsin c
NZ593474A (en) Compositions and methods for treatment of celiac disease
EA201171367A1 (ru) Винилиндазолильные соединения
WO2009026657A8 (en) Flavonoid ppar agonists
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2010006823A (es) Metodos para el tratamiento de la gota.
TNSN08400A1 (en) Organic compounds and their uses
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
UA102250C2 (ru) Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
IL207811A0 (en) Kit, composition, product or medicament for treating cognitive impairment
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
EP2207555A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF
MX2009009693A (es) Metodos para activar irs-1 y akt.

Legal Events

Date Code Title Description
FG Grant or registration